Market Cap 9.03M
Revenue (ttm) 0.00
Net Income (ttm) -14.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 33,600
Avg Vol 108,200
Day's Range N/A - N/A
Shares Out 4.20M
Stochastic %K 18%
Beta 2.04
Analysts Strong Sell
Price Target $17.60

Company Profile

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 896 9100
Website: imunon.com
Address:
997 Lenox Drive, Suite 100, Lawrenceville, United States
ProfessorGamma_
ProfessorGamma_ May. 21 at 11:37 PM
0 · Reply
TheManUpstairs
TheManUpstairs May. 21 at 2:40 PM
Getting official FDA protocol alignment and a confirmed path to BLA at the start of Phase 3 is incredibly rare for a micro-cap biotech. FDA officially signed off on Overall Survival (OS) as the primary endpoint, because the Phase 2 data was too strong to ignore. As for me, $IMNN is a massive de-risked asset (for Big pharma) trading at a ridiculous $6-7M market cap. A pure hidden gem. (ノ≧∀≦)ノ ‥…━━━★
2 · Reply
jjegglie
jjegglie May. 21 at 4:01 AM
$IMNN New all time low. No products, no prospects, criminally corrupt management. Target price: Still and forever $0
0 · Reply
TheManUpstairs
TheManUpstairs May. 20 at 8:22 PM
I see $IMNN trading close to a total capitulation phase, mirroring the exact patterns from 2017 and 2024, with major current support sitting around $1.80. This is the exact technical signal I’ve been waiting for. I am back, steadily scaling into my position (≧▽≦)/
1 · Reply
Ferryf
Ferryf May. 20 at 4:11 PM
$IMNN Engage Biologics is developing the Tethosome platform, a non-viral DNA delivery system. Engage said its platform addresses major challenges such as immune sensing and efficient cellular delivery.
0 · Reply
Ferryf
Ferryf May. 20 at 4:10 PM
$IMNN Eli Lilly acquired California-based Engage Biologics for $202 million.
0 · Reply
BA777
BA777 May. 20 at 3:57 PM
$IMNN Been watching this for a few years. At this rate it'll see 2or 3 more reverse splits combined with 100M shares diluted halfway through P3. Unless it gets bought, which I doubt...
1 · Reply
bomber1
bomber1 May. 19 at 5:06 AM
0 · Reply
bomber1
bomber1 May. 19 at 5:05 AM
$IMNN where did that citizen phenomenon go? these are the dynamics of the title that count; he didn't understand that without money they won't go anywhere, and unfortunately Imunon has no money; I hope you don't have to suddenly stop everything with a statement!!! the truth is that the title is bled dry; if it sells the minimum value of one dollar per share again, this time it will end badly!!!
2 · Reply
jjegglie
jjegglie May. 18 at 4:47 PM
$IMNN 430k new shares. I was right again.
1 · Reply
Latest News on IMNN
Imunon reports Q1 EPS (84c), consensus ($1.28)

2026-05-12T16:03:21.000Z - 11 days ago

Imunon reports Q1 EPS (84c), consensus ($1.28)


Imunon Earnings Call Transcript: Q1 2026

May 12, 2026, 11:00 AM EDT - 11 days ago

Imunon Earnings Call Transcript: Q1 2026


Imunon Earnings release: Q1 2026

May 12, 2026, 11:00 AM EDT - 11 days ago

Imunon Earnings release: Q1 2026


Imunon Quarterly report: Q1 2026

May 12, 2026, 11:00 AM EDT - 11 days ago

Imunon Quarterly report: Q1 2026


Imunon Proxy statement: Proxy filing

May 4, 2026, 8:00 AM EDT - 19 days ago

Imunon Proxy statement: Proxy filing


Imunon initiated with a Buy at Maxim

2026-04-17T12:46:27.000Z - 5 weeks ago

Imunon initiated with a Buy at Maxim


Imunon Earnings Call Transcript: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 7 weeks ago

Imunon Earnings Call Transcript: Q4 2025


Imunon Annual report: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 7 weeks ago

Imunon Annual report: Q4 2025


Imunon Earnings release: Q4 2025

Mar 31, 2026, 11:00 AM EDT - 7 weeks ago

Imunon Earnings release: Q4 2025


Imunon Earnings Call Transcript: Q3 2025

Nov 13, 2025, 11:00 AM EST - 6 months ago

Imunon Earnings Call Transcript: Q3 2025


Imunon Quarterly report: Q3 2025

Nov 13, 2025, 11:00 AM EST - 6 months ago

Imunon Quarterly report: Q3 2025


Imunon Earnings release: Q3 2025

Nov 13, 2025, 11:00 AM EST - 6 months ago

Imunon Earnings release: Q3 2025


Imunon reports Q3 EPS ($1.16) vs ($3.76) last year

2025-11-13T12:50:55.000Z - 6 months ago

Imunon reports Q3 EPS ($1.16) vs ($3.76) last year


Imunon expects cash to fund operations into Q1 of 2026

2025-11-13T12:50:47.000Z - 6 months ago

Imunon expects cash to fund operations into Q1 of 2026


Imunon showcases progress on IMNN-001 at R&D Day

2025-11-10T13:00:28.000Z - 6 months ago

Imunon showcases progress on IMNN-001 at R&D Day


Imunon to present Phase 3 OVATION 3 study of IMNN-001

2025-10-30T12:21:17.000Z - 7 months ago

Imunon to present Phase 3 OVATION 3 study of IMNN-001


Imunon to present Phase 3 OVATION trial of IMNN-001

2025-10-14T12:36:43.000Z - 7 months ago

Imunon to present Phase 3 OVATION trial of IMNN-001


Imunon Earnings Call Transcript: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 10 months ago

Imunon Earnings Call Transcript: Q2 2025


Imunon Quarterly report: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 10 months ago

Imunon Quarterly report: Q2 2025


Imunon Earnings release: Q2 2025

Aug 5, 2025, 11:00 AM EDT - 10 months ago

Imunon Earnings release: Q2 2025


Imunon sees cash runway into 4Q25

2025-08-05T12:16:44.000Z - 10 months ago

Imunon sees cash runway into 4Q25


Imunon reports Q2 EPS ($2.15), consensus ($4.99)

2025-08-05T12:10:16.000Z - 10 months ago

Imunon reports Q2 EPS ($2.15), consensus ($4.99)


Imunon board approves 15% stock dividend

2025-07-28T12:20:54.000Z - 10 months ago

Imunon board approves 15% stock dividend


IMUNON Announces Stock Dividend Boosting Shareholder Value

Jul 28, 2025, 8:05 AM EDT - 10 months ago

IMUNON Announces Stock Dividend Boosting Shareholder Value


Imunon announces 1-for-15 reverse split ratio

2025-07-23T12:15:59.000Z - 10 months ago

Imunon announces 1-for-15 reverse split ratio


IMUNON Announces Reverse Stock Split

Jul 23, 2025, 8:00 AM EDT - 10 months ago

IMUNON Announces Reverse Stock Split


Imunon Transcript: Life Sciences Investor Forum

Jun 12, 2025, 11:30 AM EDT - 1 year ago

Imunon Transcript: Life Sciences Investor Forum


Imunon Proxy statement: Proxy Filing

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing


Imunon Registration statement: Registration Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing


Imunon Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Imunon Proxy statement: Proxy Filing


Imunon Registration statement: Registration Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing


Imunon Registration statement: Registration Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing


Imunon Earnings Call Transcript: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings Call Transcript: Q1 2025


Imunon Quarterly report: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Quarterly report: Q1 2025


Imunon Earnings release: Q1 2025

May 12, 2025, 11:00 AM EDT - 1 year ago

Imunon Earnings release: Q1 2025


Imunon Registration statement: Registration Filing

Apr 4, 2025, 8:00 AM EDT - 1 year ago

Imunon Registration statement: Registration Filing


Imunon Earnings Call Transcript: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings Call Transcript: Q4 2024


Imunon Annual report: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Annual report: Q4 2024


Imunon Earnings release: Q4 2024

Feb 27, 2025, 11:00 AM EST - 1 year ago

Imunon Earnings release: Q4 2024


IMUNON Appoints Douglas V. Faller, M.D.

Feb 10, 2025, 8:05 AM EST - 1 year ago

IMUNON Appoints Douglas V. Faller, M.D.


ProfessorGamma_
ProfessorGamma_ May. 21 at 11:37 PM
0 · Reply
TheManUpstairs
TheManUpstairs May. 21 at 2:40 PM
Getting official FDA protocol alignment and a confirmed path to BLA at the start of Phase 3 is incredibly rare for a micro-cap biotech. FDA officially signed off on Overall Survival (OS) as the primary endpoint, because the Phase 2 data was too strong to ignore. As for me, $IMNN is a massive de-risked asset (for Big pharma) trading at a ridiculous $6-7M market cap. A pure hidden gem. (ノ≧∀≦)ノ ‥…━━━★
2 · Reply
jjegglie
jjegglie May. 21 at 4:01 AM
$IMNN New all time low. No products, no prospects, criminally corrupt management. Target price: Still and forever $0
0 · Reply
TheManUpstairs
TheManUpstairs May. 20 at 8:22 PM
I see $IMNN trading close to a total capitulation phase, mirroring the exact patterns from 2017 and 2024, with major current support sitting around $1.80. This is the exact technical signal I’ve been waiting for. I am back, steadily scaling into my position (≧▽≦)/
1 · Reply
Ferryf
Ferryf May. 20 at 4:11 PM
$IMNN Engage Biologics is developing the Tethosome platform, a non-viral DNA delivery system. Engage said its platform addresses major challenges such as immune sensing and efficient cellular delivery.
0 · Reply
Ferryf
Ferryf May. 20 at 4:10 PM
$IMNN Eli Lilly acquired California-based Engage Biologics for $202 million.
0 · Reply
BA777
BA777 May. 20 at 3:57 PM
$IMNN Been watching this for a few years. At this rate it'll see 2or 3 more reverse splits combined with 100M shares diluted halfway through P3. Unless it gets bought, which I doubt...
1 · Reply
bomber1
bomber1 May. 19 at 5:06 AM
0 · Reply
bomber1
bomber1 May. 19 at 5:05 AM
$IMNN where did that citizen phenomenon go? these are the dynamics of the title that count; he didn't understand that without money they won't go anywhere, and unfortunately Imunon has no money; I hope you don't have to suddenly stop everything with a statement!!! the truth is that the title is bled dry; if it sells the minimum value of one dollar per share again, this time it will end badly!!!
2 · Reply
jjegglie
jjegglie May. 18 at 4:47 PM
$IMNN 430k new shares. I was right again.
1 · Reply
jjegglie
jjegglie May. 18 at 4:44 PM
$IMNN Use the butter coated doxorubicin trials as a guide. The current garbage has a full 6 years left. And they clearly indicated last week they fully intend to use every single day of it. No surprise when you properly understand celsion. Then, once it fails, they will go cohort shopping. Find a group for whom the treatment worked when administered on the second Tuesday of the month while the patient held their left pinky on their nose and run another trial on those parameters. It will never end until they are stopped. That's why its so vital to tell the unvarnished truth about this stock promotion scam corporation. Literally saves lives and investor fortunes
0 · Reply
donoho1
donoho1 May. 18 at 3:42 PM
$IMNN POS stock.
2 · Reply
bomber1
bomber1 May. 18 at 3:37 PM
$IMNN another capital increase!! it seems like around 350,000 shares...
2 · Reply
KBernardBio
KBernardBio May. 18 at 1:35 PM
$IMNN How many 15:1 RS splits ? Many have lost 99.95% since 4 years. This might be amongst the most scam company out there. The crooked Management are criminals. Shame on you !
2 · Reply
ConcernedCitizen23
ConcernedCitizen23 May. 15 at 9:55 PM
$IMNN 10% owner
2 · Reply
ZacksSCR
ZacksSCR May. 14 at 7:54 PM
$IMNN On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27 https://buff.ly/vWLouf6
0 · Reply
jjegglie
jjegglie May. 13 at 8:04 PM
$IMNN Yet another newb who hasn't performed a single shred of due diligence on celsion. This is a dilution scam. Celsion doesn't give a single shit about cancer. The company exists to keep management paid at the expense of dupes buying the continuous dilution cycles and sick people's health. Every single drug company on the planet has had nearly 2 years to review the p2 data (which, by the way, is fatally flawed and statistically insignificant) and passed on buying the company, which is a rounding error for any legitimate drug company. Also, they dont have a cash runway of $4.7 million. They had a cash runway of $4.7 million. Its currently halfway through the next quarter. The cash balance is half that at best and they will dilute any day now.
2 · Reply
TheManUpstairs
TheManUpstairs May. 13 at 7:48 PM
Let’s be realistic about $IMNN : looking at their current cash runway of just $4.8M against their quarterly burn rate, the company doesn't even have the capital to fund the enrollment of the first 80 patients. But that’s completely missing the point here. Imunon was never meant to finish the OVATION 3 trial independently The strategy here is clear: 1) Secure near-term bridge financing to keep the lights on and stabilize the stock 2) Leverage the FDA-approved protocol to sign a major strategic partnership or buy-out. This is a M&A play. ( ˘▽˘)っ♨
1 · Reply
bomber1
bomber1 May. 13 at 7:17 PM
$IMNN it goes down because they didn't say anything new today; indeed biblical times; very long; they talk about an enrollment of 80 patients by the end of 2027!! but do you realize? 80 patients? but we're joking; on a global phase 3 trial of an oncology product, in a year and a half they still have only 80 patients? will never be able to reach the goal
1 · Reply
LKDOG
LKDOG May. 13 at 6:31 PM
$IMNN 6% drop ? Does not make sense . Will see how it goes 🤷🏻‍♂️
0 · Reply
bxp2390
bxp2390 May. 13 at 1:56 PM
$IMNN I hate to ask you all to do a valuation exercise, but try this "prompt"(even if you choose to do that on your favorite AI). Prompt to any AI: "If a biotech in Phase 3 trials gets approved in 4 years for first-line treatment in ovarian cancer, what could be the market capitalization on approval given the market for ovarian cancer in the US? Then, assume a 25% chance of the FDA approving the drug (much less than the general P3 approval percentage), and discount the valuation to today. What could the company be worth today?" Obviously the bears are going to say that approval probability is zero and modify the prompt for that and we know what the output will be too. But this is the uncertainty here that we all are taking different sides on.
2 · Reply
jjegglie
jjegglie May. 12 at 6:19 PM
$IMNN Straight from the press release. Enrollment won't be completed for another 3 years🤣🤣. I told this board that the trial wouldn't go one day less than the full 7 years, but all the bots, penny stock pooper scoopers and paid pushers merely blocked me for it. Celsion doesn't give a single shit about cancer. This trial is simply a way for management to continue selling worthless shares and maintain their exorbitant salaries. Hopefully, this revelation today will actually save some longs from losing all their money.
0 · Reply